Frédéric Knoflach

Title: Frédéric Knoflach: Innovator in GABA A Modulation

Introduction

Frédéric Knoflach is a notable inventor based in Arlesheim, Switzerland. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that act as positive allosteric modulators of GABA A receptors. His work is crucial for advancing therapeutic options in various neurological conditions.

Latest Patents

Frédéric Knoflach holds a patent for "Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators." This patent includes compounds characterized by a general formula (I), where R, R, R, R, R, and X are defined within the patent documentation. The patent outlines compositions that include these compounds and methods for their use, showcasing his innovative approach to drug development. He has 1 patent to his name.

Career Highlights

Knoflach is currently associated with Hoffmann-La Roche Inc., a leading global healthcare company. His role involves research and development aimed at creating new therapeutic agents that can improve patient outcomes. His expertise in pharmacology and medicinal chemistry has positioned him as a key player in his field.

Collaborations

Throughout his career, Frédéric has collaborated with esteemed colleagues, including Giuseppe Cecere and Jaclyn Ivy Wamsteeker Cusulin. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of their shared research goals.

Conclusion

Frédéric Knoflach's contributions to the field of pharmacology, particularly through his patent on GABA A modulators, highlight his role as an influential inventor. His work continues to pave the way for new therapeutic developments in neuroscience.